BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$275.60 USD
-2.61 (-0.94%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $275.67 +0.07 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Bio-Rad Laboratories (BIO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$426.25 | $480.00 | $365.00 | 53.21% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Bio-Rad Laboratories comes to $426.25. The forecasts range from a low of $365.00 to a high of $480.00. The average price target represents an increase of 53.21% from the last closing price of $278.21.
Analyst Price Targets (4 )
Broker Rating
Bio-Rad Laboratories currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 25% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
Not Identified | Not Identified | Not Identified | Not Identified | Not Identified |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 4 |
Average Target Price | $426.25 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 140 of 252 |
Current Quarter EPS Est: | 2.04 |